Programmed cell death protein 1 (PD‐1) inhibitor monotherapy is the standard second‐line treatment for esophageal squamous cell carcinoma (ESCC), but the clinical response and survival outcomes still remain unsatisfactory. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.